Publications
Featured Publication
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
N Engl J Med 2021; 384:717-726
View
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study
J Clin Psychiatry 2022; 83(3):21m14316
View
Xanomeline’s Activity in Rodent Models of Psychosis: Role of Central Muscarinic Receptors and Augmentation by Risperidone and Aripiprazole [Poster #T42].
2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; 2021 June 1-4.
View
Characterizing the Antipsychotic Activity and Safety Profile of the Novel Muscarinic Agonist KarXT (Xanomeline + Trospium ): Primary and Secondary Results from a Phase 2 Placebo Controlled Trial in Schizophrenia [Poster #W47].
2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; 2021 June 1-4.
View
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
N Engl J Med 2021; 384:717-726
View
The M1/M4 agonist xanomeline, in combination with the peripheral anticholinergic trospium, is effective for acute treatment of schizophrenia: results of a Phase 2 RCT comparing KarXT vs placebo [Poster #M110].
59th Annual Meeting of The American College of Neuropsychopharmacology (ACNP); 2020 Dec 6-9.
View
Phase 2 trial results of KarXT (xanomeline + trospium) in patients with schizophrenia: superior efficacy to placebo across positive and negative symptoms and a favorable safety/tolerability profile [Oral presentation].
33rd European College of Neuropsychopharmacology (ECNP) Congress; 2020 Sep 12-15.
View
KarXT (a new mechanism antipsychotic based on xanomeline), is superior to placebo in patients with schizophrenia: Phase 2 clinical trial results [Oral presentation].
2020 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; 2020 May 29-30.
View